Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesThe Effect of Prescription Omega-3 Fatty Acids on Body Weight After 8 to 16 Weeks of Treatment for Very High Triglyceride Levels
Postgraduate Medicine, 09/30/09
Bays HE et al. – When coadministered with fenofibrate for up to 16 weeks, the modest daily caloric contribution of P–OM3 (Lovaza 4 g/day) did not alter body weight or waist circumference compared with baseline or compared with fenofibrate plus placebo in patients with very high triglyceride levels.
Methods- This analysis evaluated 167 dyslipidemic (triglycerides: >= 500 mg/dL and < 1300 mg/dL), overweight/obese (body mass index [BMI] >= 25 kg/m2 and <= 43 kg/m2) patients aged 18 to 79 years.
- Data were derived from an 8–week, randomized, double–blinded, placebo–controlled, parallel–group trial comparing P–OM3 4 g/day + fenofibrate 130 mg/day (n = 84) versus placebo (4 g/day of corn oil) + fenofibrate 130 mg/day (n = 83), and an 8–week open–label extension (n = 117), during which all subjects received P–OM3 + fenofibrate.
- Subjects who received P–OM3 + fenofibrate continued the same treatment in the extension phase (non–switchers; n = 59).
- Those who initially received corn oil placebo + fenofibrate received P–OM3 + fenofibrate in the extension phase (switchers; n = 58).
- During the 8–week double–blind phase in subjects receiving fenofibrate, the addition of P–OM3 (versus placebo) did not significantly change median (minimum, maximum) body weight or waist circumference.
- In the 8–week extension phase, non–switchers and switchers did not differ in median change from the end of the double–blind phase in body weight, or waist circumference.
Related Articles
The Insulin Effect on Cerebrocortical Theta Activity Is Associated with Serum Concentrations of Saturated Nonesterified Fatty Acids
Journal of Clinical Endocrinology and Metabolism, 10/15/09
Relevance Score: 88%
Marine Omega-3 Fatty Acid Intake: Associations with Cardiometabolic Risk and Response to Weight Loss Intervention in The Look AHEAD Study
Diabetes Care, 11/05/09
Relevance Score: 87%
Omega-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: a prospective cohort study from the Age-Related Eye Disease Study
American Journal of Clinical Nutrition, 10/20/09
Relevance Score: 81%
Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+-induced permeability transition
Journal of Molecular and Cellular Cardiology, 11/17/09
Relevance Score: 80%
Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV
American Journal of Clinical Nutrition, 10/28/09
Relevance Score: 80%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins
International Journal of Dermatology, 12/03/09
Valsartan and aliskiren (Valturna): Combination of an angiotensin receptor blocker with direct renin inhibitor approved for the treatment of hypertension
Formulary , 12/02/09
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Vascular Health and Risk Management, 12/01/09
Sponsor
Article Search
Sponsor